New methods of nuclear medicine in thyroid
- PDF / 156,730 Bytes
- 2 Pages / 612 x 792 pts (letter) Page_size
- 74 Downloads / 227 Views
ArticleID
: 202
ArticleDOI
: 10.1186/1756-6614-8-S1-A14
ArticleCitationID
: A14
ArticleSequenceNumber
: 14
ArticleCategory
: Meeting abstract
ArticleFirstPage
: 1
ArticleLastPage
: 2
ArticleHistory
:
ArticleCopyright
Kaminski; licensee BioMed Central Ltd.2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits : unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
RegistrationDate OnlineDate
: 2015–6–22 : 2015–6–22
Aff1
Military Institute of Medicine, Warsaw, Poland Spring School of Thyroidology organized by the Polish Thyroid Association 2014: abstracts of invited lectures Spring School of Thyroidology organized by the Polish Thyroid Association 2014 Miedzyzdroje, Poland 23-24 May 2014 Publication of this supplement was funded by the Polish Thyroid Association. The Supplement Editors declare that they have no competing interests. Meeting abstracts Andrzej Lewinski Mariusz Stasiolek
Since radioiodine was first introduced in the therapy of hyperthyroidism in the 1940s, in the 21st century, thyroid has become the arena of development of nuclear-molecular biology imaging. SPECT and PET technics allow the visualization of small particles like peptides and their receptors. In PET with 18F-FDG we can assess metabolic activity of thyroid tumours. If there is higher metabolic activity, the tumour is more aggressive and the prognosis poorer. These novel methods let us observe the primary lesion and metastatic processes in iodine avid differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Potentially, each particle triggered with a radioisotope which is involved in a cell structure and/or its metabolism can be useful in molecular imaging. The first group of molecules used in radioisotope molecular imaging is peptide receptors agonists and antagonists. Somatostatin receptors are overexpressed in DTC and MTC. Therefore, somatostatin analogues triggered with radioisotopes are used in either imaging (99mTechnetium, 111Indium, 68Gallium) or treatment (90Yttrium, 177 Lutetium) of these malignancies. Implementation of appropriate chelator allowed the creation of radiopharmaceuticals conjugated with either SPECT or PET isotopes. It seems that the best method for visualization of MTC is PET with 18F-DOPA up till now. Recently, new radiolabelled tracers for MTC visualizations are under investigation: cholecystokinin – 2 (CKK-2) gastrin receptor ligand radiolabelled with 111 Indium and glucagon – like peptide -1 (GLP – 1) labelled with 99mTechnetium. References 1. Pepe G, Moncayo R, Bombardieri E, Chiti A: Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging 2012,39(Suppl 1):S41-S51. 2. W
Data Loading...
